Trending...
- Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
- ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
- UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
CARLSBAD, Calif. - Washingtoner -- Universal Sequencing Technology Corporation (UST), a global leader in genomic sequencing innovations, announced today the release of a high throughput microbial WGS library preparation kit enabling 2nd-generation short-read sequencers to produce long-range results in a much affordable price for microbial genomes.
With this special high throughput kit, users can pool more microbial samples in one sequencing run in combination with our 96-well plate multiplexing primers, which includes 10-base indexes and significantly reduces NGS library preparation and sequencing costs.
Researchers will now be able to take advantage of the ultra-long linked-read results to provide unparalleled genomic information with up to 200Kb gDNA fragments for microbial genome analyses.
With TELL-Seq technology, we've made NGS library preparation easy. Our products effectively improve performance, process time, and budget across a broad range of sample types with a proven track record.
Dr. Tom Chen, Chief Scientific Officer of UST, stated, "We are further streamlining the TELL-seq workflow with reduced cost per reaction and expanded throughput in response to increased customer demands."
More on Washingtoner
UST's TELL-Seq is a patent-pending transposase-based linked-read library preparation technology that enables short-read 2nd generation DNA sequencing platforms, such as Illumina sequencers, to produce long-range sequencing results (averaging linked-read molecule length greater than 40kb and up to 200kb). With a simple workflow, a sequencing-ready Illumina library can be prepared in PCR tubes in about 3 hours, cost-effective and no special lab equipment needed.
ABOUT UST
Universal Sequencing Technology Corporation (UST), a Boston and San Diego-based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to developing the most advanced DNA sequencing technologies and has filed more than 20 PCT patent applications covering linked read NGS library preparation, single-cell sequencing, and groundbreaking 3rd-generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.
www.universalsequencing.com
With this special high throughput kit, users can pool more microbial samples in one sequencing run in combination with our 96-well plate multiplexing primers, which includes 10-base indexes and significantly reduces NGS library preparation and sequencing costs.
Researchers will now be able to take advantage of the ultra-long linked-read results to provide unparalleled genomic information with up to 200Kb gDNA fragments for microbial genome analyses.
With TELL-Seq technology, we've made NGS library preparation easy. Our products effectively improve performance, process time, and budget across a broad range of sample types with a proven track record.
Dr. Tom Chen, Chief Scientific Officer of UST, stated, "We are further streamlining the TELL-seq workflow with reduced cost per reaction and expanded throughput in response to increased customer demands."
More on Washingtoner
- ARADIA (Est. 1991) Launches First B2A Partner Program for AI
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- Spokane: Drugs and Guns Seized in a Counter Narcotics Investigation
- Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
- The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
UST's TELL-Seq is a patent-pending transposase-based linked-read library preparation technology that enables short-read 2nd generation DNA sequencing platforms, such as Illumina sequencers, to produce long-range sequencing results (averaging linked-read molecule length greater than 40kb and up to 200kb). With a simple workflow, a sequencing-ready Illumina library can be prepared in PCR tubes in about 3 hours, cost-effective and no special lab equipment needed.
ABOUT UST
Universal Sequencing Technology Corporation (UST), a Boston and San Diego-based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to developing the most advanced DNA sequencing technologies and has filed more than 20 PCT patent applications covering linked read NGS library preparation, single-cell sequencing, and groundbreaking 3rd-generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.
www.universalsequencing.com
Source: Universal Sequencing Technology Corporation
Filed Under: Health
0 Comments
Latest on Washingtoner
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
- Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free
- Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity
- PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
- Spokane: City And County Seek Federal Grant to Plan for Road Network Wildfire Resilience
- The Great Junk Hunt Returns to Monroe: Kick Off Your Holiday Shopping at the Ultimate Vintage Treas
- AI Trading Agents Track Aerospace and Defense US Stocks Amid Rising Technology Investment (SATS, GILT, TSAT, IREN, JOBY, LUNR)
- KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
- Evluma's RoadMax Edge Roadway Luminaires Earn DarkSky Approved Status
- Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)
- New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
- Tacoma: Public Hearing for Off-Street Parking Code Update Set for December 1
- Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
- Spokane: SPD Makes an Arrest in Yesterday's Early Morning Shooting
- Spokane: Mayor Brown Introduces 2027-2028 Budget Proposal
- Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
- IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
- FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
- Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
